{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:47:25Z","timestamp":1790419645700,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["132677"],"award-info":[{"award-number":["132677"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004144","name":"Liverpool John Moores University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004144","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office of Hungary","doi-asserted-by":"crossref","award":["RRF-2.3.1-21-2022-00015"],"award-info":[{"award-number":["RRF-2.3.1-21-2022-00015"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office of Hungary","doi-asserted-by":"crossref","award":["TKP2021-EGA-16"],"award-info":[{"award-number":["TKP2021-EGA-16"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"name":"E\u00f6tv\u00f6s L\u00f3r\u00e1nd Research Network"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>It has previously been shown that the peptide (34Pro,35Phe)CGRP27\u201337 is a potent calcitonin gene-related peptide, CGRP receptor antagonist, and in this project we aimed to improve the antagonist potency through the structural modification of truncated C-terminal CGRP peptides.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six peptide analogues were synthesized and the anti-CGRP activity confirmed using both in vitro and in vivo studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>A 10 amino acid-containing peptide VPTDVGPFAF-NH2 (P006) was identified as a key candidate to take forward for in vivo evaluation, where it was shown to be an effective antagonist after intraperitoneal injection into mice. P006 was formulated as a preparation suitable for nasal administration by spray drying with chitosan to form mucoadhesive microcarriers (9.55 \u00b1 0.91 mm diameter) and a loading of 0.2 mg peptide per 20 mg dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The project has demonstrated the potential of these novel small peptide CGRP antagonists, to undergo future preclinical evaluation as anti-migraine therapeutics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgad081","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T04:13:32Z","timestamp":1695528812000},"page":"1581-1589","source":"Crossref","is-referenced-by-count":6,"title":["Novel peptide calcitonin gene-related peptide antagonists for migraine therapy"],"prefix":"10.1093","volume":"75","author":[{"given":"Patrick M","family":"Killoran","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University , Liverpool, L3 3AF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Capel","sequence":"additional","affiliation":[{"name":"NHS Health Education England , Victoria House, Fulbourn, Cambridge, CB21 5XB ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"D\u2019Aloisio","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University , Liverpool, L3 3AF ,","place":["United Kingdom"]},{"name":"AmbioPharm, Inc. , 1024 Dittman Court, North Augusta, SC 29842 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schofield","sequence":"additional","affiliation":[{"name":"EaStCHEM School of Chemistry, The University of Edinburgh , Joseph Black Building, David, Brewster Road, Edinburgh, EH14 4AS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Acz\u00e9l","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, University of P\u00e9cs Medical School , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]},{"name":"E\u00f6tv\u00f6s Lorand Research Network, Chronic Pain Research Group, University of P\u00e9cs , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kata","family":"B\u00f6lcskei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, University of P\u00e9cs Medical School , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]},{"name":"E\u00f6tv\u00f6s Lorand Research Network, Chronic Pain Research Group, University of P\u00e9cs , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Helyes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, University of P\u00e9cs Medical School , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]},{"name":"E\u00f6tv\u00f6s Lorand Research Network, Chronic Pain Research Group, University of P\u00e9cs , Szigeti \u00fat 12, P\u00e9cs ,","place":["Hungary"]},{"name":"PharmInVivo Ltd. , Szondi Gy. u. 10. H-7629 , P\u00e9cs ,","place":["Hungary"]},{"name":"National Laboratory for Drug Research and Development , Magyar tud\u00f3sok krt. 2, H-1117 Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"von Mentzer","sequence":"additional","affiliation":[{"name":"Innovipharm Limited , 2 Woodlands Lane, West Kirby, Wirral, CH48 8D ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Kendall","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University , Liverpool, L3 3AF ,","place":["United Kingdom"]},{"name":"Innovipharm Limited , 2 Woodlands Lane, West Kirby, Wirral, CH48 8D ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R","family":"Coxon","sequence":"additional","affiliation":[{"name":"EaStCHEM School of Chemistry, The University of Edinburgh , Joseph Black Building, David, Brewster Road, Edinburgh, EH14 4AS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9786-2074","authenticated-orcid":false,"given":"Gillian A","family":"Hutcheon","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University , Liverpool, L3 3AF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2024103012281155700_CIT0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1129-2377-14-1","article-title":"Migraine: the seventh disabler","volume":"14","author":"Steiner","year":"2013","journal-title":"J Headache Pain"},{"key":"2024103012281155700_CIT0002","first-page":"1237","article-title":"CGRP inhibitors for migraine prophylaxis: a safety review","volume-title":"Expert Opin Drug Saf","author":"Rivera-Mancilla","year":"2020"},{"key":"2024103012281155700_CIT0003","first-page":"250","article-title":"Calcitonin gene related peptide and migraine","volume-title":"Curr Opin Neurol","author":"Karsan","year":"2015"},{"key":"2024103012281155700_CIT0004","first-page":"338","article-title":"CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic","volume-title":"Nat Rev Neurol","author":"Edvinsson","year":"2018"},{"key":"2024103012281155700_CIT0005","first-page":"951","article-title":"Calcitonin gene-related peptide modulators\u2014the history and renaissance of a new migraine drug class","volume-title":"Headache","author":"Hargreaves","year":"2019"},{"key":"2024103012281155700_CIT0006","first-page":"6600","article-title":"Blocking the CGRP pathway for acute and preventative treatment of migraine: the evolution of success","volume-title":"J Med Chem","author":"Dubowchik","year":"2020"},{"key":"2024103012281155700_CIT0007","first-page":"100053","article-title":"Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine","volume-title":"Med Drug Discov","author":"Moreno-Ajona","year":"2020"},{"key":"2024103012281155700_CIT0008","first-page":"1153","article-title":"Zavegepant nasal spray for the acute treatment of migraine: a Phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial","volume-title":"Headache","author":"Croop","year":"2022"},{"key":"2024103012281155700_CIT0009","first-page":"664","article-title":"Medications approved for preventing migraine headaches","volume-title":"Am J Med","author":"Spindler","year":"2020"},{"key":"2024103012281155700_CIT0010","first-page":"272","article-title":"Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies","volume-title":"Curr Opin Neurol","author":"Mitsikostas","year":"2017"},{"key":"2024103012281155700_CIT0011","first-page":"1","article-title":"Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study","volume":"22","author":"Ashina","year":"2021","journal-title":"Headache"},{"key":"2024103012281155700_CIT0012","first-page":"033310242311521","article-title":"Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis","volume-title":"Cephalalgia","author":"Messina","year":"2023"},{"key":"2024103012281155700_CIT0013","first-page":"101","article-title":"Migraine and CGRP monoclonal antibodies: a review of cardiovascular side effects and safety profile","volume":"7","author":"Boldig","year":"2020","journal-title":"Int J Neurol Neurother"},{"key":"2024103012281155700_CIT0014","first-page":"2468","article-title":"Nasal delivery of acute medications for migraine: the upper versus lower nasal space","volume-title":"J. Clin. Med","author":"Martin","year":"2021"},{"key":"2024103012281155700_CIT0015","first-page":"254","article-title":"Nasal drug delivery\u2014recent developments and future prospects","volume-title":"J Control Release","author":"Illum","year":"2012"},{"key":"2024103012281155700_CIT0016","first-page":"285","article-title":"Pharmacokinetic profile of Almiditan nasal spray during and outside migraine attacks","volume-title":"Br J Clin Pharmacol","author":"Roon","year":"1999"},{"key":"2024103012281155700_CIT0017","first-page":"309","article-title":"Trends in peptide drug discovery","volume-title":"Nat Rev Drug Discov","author":"Muttenthaler","year":"2021"},{"key":"2024103012281155700_CIT0018","first-page":"2700","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume-title":"Bioorg Med Chem","author":"Lau","year":"2018"},{"key":"2024103012281155700_CIT0019","first-page":"1409","article-title":"PepTheDia: database and structural composition analysis of approved peptide therapeutics and diagnostics","volume-title":"Drug Discov Today","author":"D\u2019Aloisio","year":"2021"},{"key":"2024103012281155700_CIT0020","first-page":"7889","article-title":"Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor","volume-title":"J Med Chem","author":"Miranda","year":"2008"},{"key":"2024103012281155700_CIT0021","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/jm050613s","article-title":"Identification of the key residue of calcitonin gene related peptide (CGRP) 27\u221237 to obtain antagonists with picomolar affinity at the CGRP receptor","volume":"49","author":"Lang","year":"2006","journal-title":"J Med Chem"},{"key":"2024103012281155700_CIT0022","first-page":"117","article-title":"From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor","volume-title":"J Med Chem","author":"Rist","year":"1998"},{"key":"2024103012281155700_CIT0023","first-page":"153","article-title":"CGRP 27\u201337 analogues with high affinity to the CGRP receptor show 1 antagonistic properties in a rat blood flow assay","volume-title":"Regul Pept","author":"Rist","year":"1999"},{"key":"2024103012281155700_CIT0024","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psc.1358","article-title":"Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists","volume":"17","author":"Yan","year":"2011","journal-title":"J Pept Sci"},{"key":"2024103012281155700_CIT0025","first-page":"1352","article-title":"A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine","volume-title":"J Pharm Pharmacol","author":"Von Mentzer","year":"2020"},{"key":"2024103012281155700_CIT0026","first-page":"1583","article-title":"Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems","volume-title":"Adv Drug Del Rev","author":"Takeuchi","year":"2005"},{"key":"2024103012281155700_CIT0027","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1021\/acs.biochem.8b00787","article-title":"Fluorinated prolines as conformational tools and reporters for peptide and protein chemistry","volume":"57","author":"Verhoork","year":"2018","journal-title":"Biochemistry"},{"key":"2024103012281155700_CIT0028","first-page":"8317","article-title":"Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains","volume-title":"Biochem","author":"Carpenter","year":"2001"},{"key":"2024103012281155700_CIT0029","first-page":"492","article-title":"Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor","volume-title":"Nature","author":"Liang","year":"2018"},{"key":"2024103012281155700_CIT0030","first-page":"189","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume-title":"J Control Release","author":"Casettari","year":"2014"},{"key":"2024103012281155700_CIT0031","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/CBO9780511841378.109","article-title":"Intranasal morphine","volume-title":"The Essence of Analgesia and Analgesics","author":"Snegovskikh","year":"2010"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/12\/1581\/60218908\/rgad081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/12\/1581\/60218908\/rgad081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:23:03Z","timestamp":1730308983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/75\/12\/1581\/7281582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgad081","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,12,1]]}}}